Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Evazarsen in Chronic Heart Failure With Reduced Ejection Fraction
NCT04836182Phase 2Completed
- Sponsor
- Ionis Pharmaceuticals
- Start
- Jun 2021
- Primary completion
- Oct 2022
- Modality
- Small Interfering RNA (siRNA), Modified DNA Oligonucleotides, Single-strand DNA
- Countries
- 3
01
Overview
Phase 2, randomised, double-blind trial in heart failure with reduced ejection fraction (HFrEF) comparing Evazarsen with Placebo (2 arms). Primary endpoint: Percent Change in Plasma Angiotensinogen Concentration From Baseline to Study Day 85. Started Jun 2021; status: completed.
02
Drugs
evazarsen
03
Conditions
heart failure with reduced ejection fraction (HFrEF)
Beyond the preview
Go deeper on NCT04836182.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04836182.